Takeda Initiates Phase 3 Trial For Lung Cancer Drug

Takeda Bio Development Center Limited, will evaluate motesanib in combination with chemotherapy in patients with advanced non-squamous non-small cell lung cancer (NSCLC).

Motesanib (development code: AMG 706) is an investigational, orally administered small molecule antagonist of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptors, and stem cell factor receptor.

Source: http://www.asianscientist.com/tech-pharma/takeda-initiates-phase-3-trial-motesanib-nsclc-2012/